Articles

Poll

Podcasts

Slideshows

Videos

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

This analysis presented at AAAAI suggests that the experimental OMIT delivery of allergens via toothpaste may allow for a safer alternative to other immunotherapies.


Study Suggest Oral Mucosal Immunotherapy May Offer Safer, More Convenient Option

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

Viaskin Milk Patch Returns Mixed Results in Phase 1/2 Trial

Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.

Robert Wood, MD: OUtMATCH Informs Omalizumab Use in Pediatric Food Allergy

Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group. 

OUtMATCH: Omalizumab Proves Utility in Multiple Food Allergies for Pediatric, Adult Patients

In this interview, Ebisawa discusses his team’s recent research into the frequently-discussed non-injector epinephrine alternative neffy.


Motohiro Ebisawa, MD, PhD: Phase 3 Findings on Neffy for Pediatric Patients At-Risk of Anaphylaxis

Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.

Robert Wood, MD: Impact of Omalizumab Approval on Management of Pediatric Food Allergy

This analysis suggests that the financial burden of oral food challenges may be offset slightly through the use of FPIES.

Children with Food Allergies May Benefit from Home Reintroduction of FPIES

These data, to be presented at AAAAI, indicate that following 12 and 24 months of immunotherapy with BMOIT, desensitization to milk products can be observed among patients.

Baked Milk Oral Immunotherapy Leads to Improvements for Patients with Cow’s Milk Allergy 

The approval is based upon phase 3 findings from the OUtMATCH study, representing the first treatment for adult and pediatric patients with accidental exposure to 1 or more food allergens.


FDA Approves Omalizumab as First Treatment of 1 or More Food Allergies for Children, Adults 

These data also showed that basophil activation test can be a particularly precise biomarker of allergy compared to tolerance among children who are egg-allergic children.
